A. Shimoni

A. Nagler, N. Amariglio, G. Saglio, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Changes in Gene Expression Pattern following Granulocyte Colony-Stimulating Factor Administration to Normal Stem Cell Sibling Donors

A. Nagler, N. Amariglio, G. Rechavi, 2006, Acta Haematologica.

The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation

M. Labopin, A. Nagler, R. Yerushalmi, 2018, Leukemia.

Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.

A. Nagler, M. Besser, A. Shimoni, 2019, Current research in translational medicine.

CAR T cells induce a complete response in refractory Burkitt Lymphoma

A. Nagler, M. Besser, A. Shimoni, 2018, Bone Marrow Transplantation.

Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation

M. Labopin, A. Nagler, M. Mohty, 2019, British journal of haematology.

Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia

A. Nagler, M. Leiba, R. Arnold, 2009, Leukemia.

Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response

J. Schachter, A. Nagler, G. Markel, 2020, Molecular carcinogenesis.

Halofuginone inhibits NF‐κB and p38 MAPK in activated T cells

A. Nagler, M. Leiba, L. Cahalon, 2006 .

Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced‐intensity allografting

N. Kröger, A. Zander, A. Nagler, 2012, British journal of haematology.

A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD).

A. Nagler, L. Trakhtenbrot, N. Amariglio, 2008, Leukemia research.

LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell transplantation

A. Nagler, R. Yerushalmi, A. Shimoni, 2020, Bone Marrow Transplantation.

Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells

A. Nagler, A. Toren, M. Besser, 2021, Leukemia & lymphoma.

Apoptotic cells in allogeneic hematopoietic stem cell transplantations: “turning trash into gold”

A. Nagler, A. Shimoni, I. Pessach, 2012, Leukemia & lymphoma.

Clinical Implications of Minimal Residual Disease Monitoring for Stem Cell Transplantation after Reduced Intensity and Nonmyeloablative Conditioning

A. Nagler, A. Shimoni, 2004, Acta Haematologica.

Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high‐risk aggressive non‐Hodgkin's lymphoma

A. Nagler, A. Shimoni, I. Hardan, 2003, British journal of haematology.

Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation

N. Ueno, S. Kornblau, R. Champlin, 2001, Bone Marrow Transplantation.

Allogeneic stem cell transplantation and targeted immunotherapy for multiple myeloma.

A. Nagler, A. Shimoni, I. Danylesko, 2013, Clinical lymphoma, myeloma & leukemia.

Regulatory T Cells in Allogeneic Stem Cell Transplantation

A. Nagler, A. Shimoni, M. Michael, 2013, Clinical & developmental immunology.

Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation

N. Kröger, D. Atanackovic, A. Zander, 2008, Haematologica.

Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation

A. Nagler, R. Yerushalmi, A. Shimoni, 2014, Annals of Hematology.

Identification of strong intron enhancer in the heparanase gene: effect of functional rs4693608 variant on HPSE enhancer activity in hematological and solid malignancies

A. Nagler, A. Shimoni, K. Beider, 2018, Oncogenesis.

Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study

A. Nagler, R. Yerushalmi, A. Shimoni, 2015, Acta Haematologica.

CT in the clinical and prognostic evaluation of acute graft-vs-host disease of the gastrointestinal tract.

M. Amitai, A. Nagler, R. Yerushalmi, 2012, The British journal of radiology.

Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma

N. Kröger, A. Nagler, A. Zander, 2004, Leukemia.

Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and

M. Labopin, I. Yakoub-Agha, H. Sengeløv, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The expanding horizon of immunotherapy in the treatment of malignant disorders: Allogeneic hematopoietic stem cell transplantation and beyond

A. Nagler, A. Shimoni, P. Tsirigotis, 2014, Annals of medicine.

OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients

A. Nagler, N. Amariglio, M. Schwarz, 2014, European journal of haematology.

Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation.

A. Neumann, A. Nagler, T. Efferth, 2011, Antiviral research.

Treatment of Severe Acute Graft-Versus-Host Disease with Mesenchymal Stromal Cells.

A. Nagler, A. Toren, M. Weintraub, 2009 .

Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.

A. Nademanee, A. Krishnan, S. Forman, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.

N. Ueno, S. Kornblau, R. Champlin, 2000, British journal of haematology.

Radioimmunotherapy and Autologous Stem-Cell Transplantation in the Treatment of B-Cell Non-Hodgkin Lymphoma.

S. Zwas, A. Shimoni, 2016, Seminars in nuclear medicine.

Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.

A. Nagler, S. Zwas, R. Yerushalmi, 2007, Experimental hematology.

Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma

A. Nagler, A. Shimoni, 2007, Leukemia and Lymphoma.

The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft‐versus host disease after stem‐cell transplantation from unrelated donors

A. Nagler, R. Yerushalmi, A. Shimoni, 2017, American journal of hematology.

Nonmyeloablative Stem Cell Transplantation in the Treatment of Hematologic Malignancies

A. Nagler, A. Shimoni, 2006 .

Complete Remission with Incomplete Blood Count Recovery Is a Strong Predictor of Nonrelapse Mortality in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation

A. Nagler, R. Yerushalmi, A. Shimoni, 2021, Acta Haematologica.

Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients.

A. Nagler, N. Amariglio, G. Saglio, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The role of stem-cell transplantation in the treatment of marginal zone lymphoma.

A. Shimoni, 2017, Best practice & research. Clinical haematology.

Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy.

A. Nagler, A. Shimoni, J. Canaani, 2021, Clinical lymphoma, myeloma & leukemia.

Novel Immunosuppression Compounds and Experimental Therapies for Chronic Graft-Versus-Host Disease

A. Nagler, A. Shimoni, M. Michael, 2013, Acta Haematologica.

Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)

J. Panse, N. Kröger, D. Atanackovic, 2006, Bone Marrow Transplantation.

Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the

J. Esteve, R. Foà, M. Labopin, 2021, Leukemia.

Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol

A. Nagler, A. Shimoni, V. Marcu-Malina, 2022, Annals of Hematology.

ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy

A. Nagler, A. Shimoni, J. Canaani, 2022, Annals of Hematology.

Cord Blood Stem Cells for Hematopoietic Transplantation

A. Nagler, R. Yerushalmi, A. Shimoni, 2011, Stem Cell Reviews and Reports.

Isolated Extramedullary Relapse of Acute Leukemia after Allogeneic Stem Cell Transplantation: Different Kinetics and Better Prognosis than Systemic Relapse.

A. Nagler, R. Yerushalmi, A. Shimoni, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Double umbilical cord blood transplant: more than a cell dose?

A. Nagler, R. Yerushalmi, A. Shimoni, 2010, Leukemia & lymphoma.

Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party

E. Lanino, F. Locatelli, A. Prete, 2010, Haematologica.

Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas

P. Dreger, A. Shimoni, A. Sureda, 2017, Journal of clinical apheresis.

Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease

A. Nagler, L. Griškevičius, A. Shimoni, 2018, Bone Marrow Transplantation.

Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation

A. Nagler, R. Yerushalmi, A. Shimoni, 2019, European journal of haematology.

Tumor cell contamination in re-infused stem cell autografts: does it have clinical significance?

A. Shimoni, M. Körbling, 2002, Critical reviews in oncology/hematology.

Celiac Disease Resolution After Allogeneic Bone Marrow Transplantation is Associated with Absence of Gliadin-Specific Memory Response by Donor-Derived Intestinal T-cells

S. Polak‐Charcon, I. Barshack, Y. Maor, 2013, Journal of Clinical Immunology.

Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma

M. Perales, A. Nagler, S. Devlin, 2022, Leukemia.

Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC).

A. Nagler, A. Toren, D. Mankuta, 2013, American journal of blood research.

Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC

A. Nagler, J. Rowe, A. Shimoni, 2012, Hematological oncology.

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

H. Einsele, A. Zander, G. Gahrton, 2005, Blood.

Nilotinib Exhibits an in Vitro Antiviral Activity Against Human Cytomegalovirus (HCMV): Potential Clinical Applications

A. Nagler, D. Wolf, A. Shimoni, 2012 .

A phase II study of bisantrene in patients with relapsed/refractory acute myeloid leukemia

A. Nagler, R. Yerushalmi, A. Shimoni, 2020, European journal of haematology.

Mobilization regimens prior to stem-cell collection in patients with lymphoma: How to choose?

A. Shimoni, I. Hardan, 2007, Leukemia & lymphoma.

Contemporary evaluation of acute myeloid leukemia patients with long‐term survival exceeding 5 years

A. Nagler, D. Dominissini, A. Shimoni, 2022, European journal of haematology.

Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma

B. Andersson, R. Champlin, A. Shimoni, 2001, Bone Marrow Transplantation.

The HPSE Gene Insulator—A Novel Regulatory Element That Affects Heparanase Expression, Stem Cell Mobilization, and the Risk of Acute Graft versus Host Disease

A. Nagler, A. Shimoni, K. Beider, 2021, Cells.

Comparable Long-Term Outcome after Allogeneic Stem-Cell Transplantation from Sibling and Matched Unrelated Donors in AML Patients Older than 50 years. A Report on Behalf of the ALWP of EBMT.

A. Ganser, M. Labopin, D. Blaise, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Modification of heparanase gene expression in response to conditioning and LPS treatment: strong correlation to rs4693608 SNP

A. Shteingauz, A. Nagler, A. Shimoni, 2014, Journal of leukocyte biology.

Allogenic hematopoietic stem‐cell transplantation with reduced‐intensity conditioning in patients with refractory and recurrent multiple myeloma

A. Zander, A. Nagler, R. Yerushalmi, 2010, Cancer.

Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors.

A. Nagler, A. Shimoni, O. Ostrovsky, 2010, Blood.

Fludarabine and treosulfan: A novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes

A. Nagler, R. Yerushalmi, A. Shimoni, 2007, Leukemia & lymphoma.

Combined escBEACOPP-ABVD Therapy for Advanced Hodgkin’s Lymphoma Patients with High IPS Score: An Effective Regimen and Low Positive Predictive Value of Early FDG-PET/CT Scan.

A. Nagler, A. Polliack, A. Shimoni, 2007 .

The mTOR Inhibitor Everolimus Overcomes CXCR4-Mediated Resistance to Histone Deacetylase Inhibitor Panobinostat through Inhibition of p21 and Mitotic Regulators.

A. Nagler, M. Milyavsky, A. Peled, 2019, Biochemical pharmacology.

CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression

A. Nagler, A. Peled, A. Shimoni, 2022, Journal of Hematology & Oncology.

Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination.

H. Halkin, A. Nagler, S. Almog, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

N. Kröger, A. Zander, R. Brand, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation.

A. Nagler, R. Yerushalmi, A. Shimoni, 2019, Blood advances.

Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity.

A. Nagler, A. Toren, A. Shimoni, 2003, Experimental hematology.

Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced.

A. Nagler, A. Shimoni, I. Hardan, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

N. Kröger, A. Zander, R. Brand, 2009 .

Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.

N. Kröger, D. Atanackovic, A. Zander, 2009, Experimental hematology.

Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation.

H. Einsele, N. Kröger, A. Zander, 2004, Blood.

Recurrent “Retinoic acid syndrome” during induction of remission in acute promyelocytic leukemia

A. Shimoni, M. Prokocimer, Y. Maor‐Kendler, 1995, American journal of hematology.

6. NON - M Y E LOA B L A T I V E HEMATOPOIETIC STEM CELL TRANSPLANT ATION (NST) IN THE

A. Nagler, A. Shimoni, 2002 .

Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.

A. Nagler, A. Shimoni, 2002, Cancer treatment and research.

Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: Non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect

R. Champlin, A. Shimoni, I. Khouri, 2000, Current oncology reports.

Donor Lymphocyte Infusions and Second Transplantation as Salvage Treatment for Relapsed Myelofibrosis After Reduced-Intensity allografting.

N. Kröger, A. Zander, A. Nagler, 2010 .

Bloodstream infections' origins following fecal microbiota transplantation: a strain-level analysis

Itai Sharon, O. Koren, A. Nagler, 2021 .

CMV Seropositive Status Increases Heparanase SNPs Regulatory Activity, Risk of Acute GVHD and Yield of CD34+ Cell Mobilization

A. Nagler, A. Shimoni, K. Beider, 2021, Cells.

Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need.

A. Nagler, A. Shimoni, 2011, Best practice & research. Clinical haematology.

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma

J. Miguel, C. Bokemeyer, N. Kröger, 2008, Leukemia.

Isolated Extra-Medullary Relapse of Acute Leukemia after Allogeneic Stem-Cell Transplantation; Different Kinetics and Better Prognosis Than Systemic Relapse.

A. Nagler, R. Yerushalmi, A. Shimoni, 2008 .

Comparison of Outcomes After Allogeneic HSCT for Adult Patients with AML in Remission Using in the Conditioning Regimen Either I.V. Busulfex (BU) Plus Cyclophosphamide (Cy) or TBI Plus Cy: An- ALWP-EBMT Survey.

M. Labopin, A. Nagler, L. Volin, 2009 .

Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells

A. Nagler, R. Yerushalmi, M. Besser, 2020, Leukemia.

Cytomegalovirus retinitis in HIV-negative patients: a practical management approach.

G. Rahav, R. Somech, A. Shimoni, 2015, Ophthalmology.

Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in haematopoietic stem cell transplantation recipients

A. Nagler, G. Rahav, R. Yerushalmi, 2021, British journal of haematology.

Minimally Cultured or Selected Autologous Tumor-infiltrating Lymphocytes After a Lympho-depleting Chemotherapy Regimen in Metastatic Melanoma Patients

E. Segal, B. Shalmon, J. Schachter, 2009, Journal of immunotherapy.

Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced‐intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT

A. Ganser, G. Mufti, N. Kröger, 2021, British journal of haematology.

Characterization of Cyclin E Expression in Multiple Myeloma and Its Functional Role in Seliciclib-Induced Apoptotic Cell Death

A. Nagler, A. Peled, A. Shimoni, 2012, PloS one.

Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia

A. Nagler, R. Somech, R. Yerushalmi, 2016, Oncotarget.

Long‐term outcome after a treosulfan‐based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

M. Labopin, A. Nagler, M. Mohty, 2017, Cancer.

BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma.

O. Margalit, D. Givol, M. Oren, 2005, Blood.

BCL 6 is regulated by p 53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma

D. Givol, M. Oren, N. Amariglio, 2005 .

Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome–positive acute lymphoblastic leukemia

A. Nagler, R. Somech, R. Yerushalmi, 2015, Cancer.

N. Kröger, A. Zander, R. Brand, 2010, British journal of haematology.

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma

J. San Miguel, J. Miguel, C. Bokemeyer, 2008, Leukemia.

Origins of bloodstream infections following fecal microbiota transplantation: a strain-level analysis

Itai Sharon, O. Koren, A. Nagler, 2021, Blood advances.

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

R. Berger, A. Nagler, M. Leiba, 2008, Clinical Cancer Research.

Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study.

Christoph Schmid, Jordi Esteve, Roni Shouval, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A simplified method for detection of N-terminal valine adducts in patients receiving treosulfan.

A. Nagler, A. Shimoni, G. Boysen, 2019, Rapid communications in mass spectrometry : RCM.

Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

B. Shalmon, J. Schachter, A. Nagler, 2013, Clinical Cancer Research.

Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT

A. Ganser, M. Labopin, I. Yakoub-Agha, 2021, Blood Cancer Journal.

The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis.

M. Labopin, D. Blaise, A. Nagler, 2017, Blood advances.

Treatment with interferon alpha prior to discontinuation of imatinib in patients with chronic myeloid leukemia.

Arnon Nagler, Ninette Amariglio, A. Nagler, 2012, Cytokine.

Outcome differences in patients with precursor B cell acute lymphocytic leukemia over time: a retrospective analysis.

A. Nagler, A. Shimoni, A. Avigdor, 2014, The Israel Medical Association journal : IMAJ.

Anti-T Lymphocyte Globulin (ATG) Induces Generation of Regulatory T Cells, at Least Part of Them Express Activated CD44

A. Nagler, R. Yerushalmi, A. Shimoni, 2012, Journal of Clinical Immunology.

Recent compounds for immunosuppression and experimental therapies for acute graft-versus-host disease.

A. Nagler, A. Shimoni, M. Michael, 2013, The Israel Medical Association journal : IMAJ.

Conditioning Regimens Prior to Allogeneic Stem-Cell Transplantation (SCT) In Acute Leukemia: The Role Of Dose Intensity

A. Nagler, R. Yerushalmi, A. Shimoni, 2009 .

Mobilized peripheral blood stem cells compared with bone marrow from HLA‐identical siblings for reduced‐intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT

J. Gribben, G. Mufti, M. Labopin, 2012, European journal of haematology.

High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma

D. Blaise, A. Nagler, M. Mohty, 2008, Haematologica.

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.

N. Kröger, A. Zander, A. Nagler, 2004, Blood.

Adults requiring cord blood transplants but have insufficient cell doses from a single cord blood unit can receive two units with successful engraftment kinetics similar to those of children receiving a single unit

A. Nagler, R. Elhasid, R. Yerushalmi, 2011, Leukemia & lymphoma.

Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.

M. Talpaz, R. Champlin, A. Shimoni, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial.

A. Nagler, D. Mevorach, J. Rowe, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide

M. Labopin, D. Blaise, A. Nagler, 2018, Leukemia.

Monoclonal antibody-based immunotherapy for multiple myeloma.

A. Nagler, A. Shimoni, K. Beider, 2012, Immunotherapy.

Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions

A. Nagler, A. Shimoni, K. Beider, 2012, Clinical & developmental immunology.

Stem-cell dose for allogeneic hematopoietic stem cell transplantation in hematological malignancies: is more better?

A. Nagler, A. Shimoni, 2009, Leukemia & lymphoma.

A. Nagler, R. Yerushalmi, A. Shimoni, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study

R. Yerushalmi, A. Shimoni, R. Ram, 2021, Annals of Hematology.

Granulocyte-colony stimulating factor for hematopoietic stem cell donation from healthy female donors during pregnancy and lactation: what do we know?

A. Nagler, A. Shimoni, I. Pessach, 2013, Human reproduction update.

Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response

A. Nagler, A. Peled, A. Shimoni, 2020, Journal of Hematology & Oncology.

Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning

A. Nagler, R. Yerushalmi, F. Ciceri, 2014, American journal of hematology.

A randomized study comparing yttrium‐90 ibritumomab tiuxetan (Zevalin) and high‐dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma

A. Nagler, J. Rowe, I. Avivi, 2012, Cancer.

Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma

A. Nagler, D. Mevorach, R. Yerushalmi, 2020, Bone Marrow Transplantation.

Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies

J. Schachter, A. Nagler, A. Toren, 2022, Cells.

Second Malignancies after Hematopoietic Stem Cell Transplantation

A. Shimoni, I. Danylesko, 2018, Current Treatment Options in Oncology.

Carfilzomib combined with cyclosporine and methotrexate for the prevention of graft-versus-host disease after allogeneic stem-cell transplantation from unrelated donors

A. Nagler, R. Yerushalmi, A. Shimoni, 2020, Bone Marrow Transplantation.

BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study

Stephen M. Shaw, M. Andreeff, J. Dipersio, 2020, Cancer.

Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B cell lymphoma.

A. Nagler, R. Yerushalmi, D. Bomze, 2022, Transplantation and cellular therapy.

Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR‐ligand mismatch after dose‐reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma

N. Kröger, S. Iacobelli, A. Zander, 2005, British journal of haematology.

The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Arnon Nagler, Myriam Labopin, M. Labopin, 2015, Haematologica.

Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation: a survey on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

J. Esteve, M. Labopin, A. Nagler, 2015, The oncologist.

Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

R. Berger, M. Labopin, A. Nagler, 2014, Haematologica.

Immunotherapy for B-cell lymphoma

A. Nagler, A. Shimoni, 2010, Leukemia & lymphoma.

Real-World Efficacy Outcomes of FLT3-ITDmut Acute Myeloid Leukemia Patients Treated with Midostaurin in Combination with Intensive Induction.

A. Shimoni, V. Marcu-Malina, J. Canaani, 2022, Clinical lymphoma, myeloma & leukemia.

Allogeneic Hematopoietic Cell Transplantation After CAR T-cell Therapy in Large B-cell Lymphoma: Allogeneic-HCT after CAR T-cell therapy.

M. Perales, A. Nagler, S. Devlin, 2022, Transplantation and cellular therapy.

Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT

N. Kröger, M. Labopin, P. Chevallier, 2019, Blood Cancer Journal.

with multiple myeloma immunotherapy after allogeneic stem cell transplantation in patients Low-dose thalidomide and donor lymphocyte infusion as adoptive

N. Kröger, A. Zander, A. Nagler, 2013 .

Inhibition of matrix metalloproteinase-2 by halofuginone is mediated by the Egr1 transcription factor

A. Nagler, T. Peretz, A. Shimoni, 2012, Anti-cancer drugs.

The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML

M. Labopin, D. Blaise, A. Nagler, 2022, Bone Marrow Transplantation.

Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

N. Kröger, I. Yakoub-Agha, S. Stilgenbauer, 2020, Bone Marrow Transplantation.

Allogeneic Hematopoietic Stem-Cell Transplantation in Adult Acute Lymphoblastic Leukemia: Better Outcome in Transplantation during First Complete Remission and with Myeloablative Conditioning

A. Nagler, R. Yerushalmi, A. Shimoni, 2008 .

Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation.

G. Mufti, M. Labopin, P. Chevallier, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission

G. Mufti, M. Labopin, P. Chevallier, 2017, Oncotarget.

The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma

A. Nagler, A. Shimoni, S. Apter, 2014, Annals of Hematology.

Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis

A. Nagler, R. Yerushalmi, A. Shimoni, 2019, Bone Marrow Transplantation.

Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study

Christoph Schmid, Jordi Esteve, Roni Shouval, 2016, PloS one.

The occurrence of thrombosis during intensive chemotherapy treatment for acute myeloid leukemia patients does not impact on long-term survival

M. Misgav, A. Shimoni, J. Canaani, 2022, Annals of Hematology.

How to predict response to treatment and outcome in patients with gastro-intestinal acute GVHD; Can 18F-FDG-PET scanning help?

A. Shimoni, 2021, Transplantation and cellular therapy.

Haploidentical stem-cell transplant: the challenge of immune reconstitution

A. Shimoni, 2013, Leukemia & lymphoma.

Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation

A. Nagler, R. Yerushalmi, A. Shimoni, 2022, Haematologica.

Relapse of acute leukemia after a second allogeneic stem- cell transplantation; Is there any hope for cure?

A. Shimoni, 2022, Bone Marrow Transplantation.

Second malignancies after allogeneic stem cell transplantation with reduced-intensity conditioning: is the incidence reduced?

A. Shimoni, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Hematopoietic Stem-Cell Transplantation in AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: The Role of Dose-Intensity.

A. Nagler, R. Yerushalmi, A. Shimoni, 2005 .

Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using combined morphologic and fluorescence in situ hybridization analysis.

A. Nagler, L. Trakhtenbrot, N. Amariglio, 2004, Experimental Hematology.

Conditioning

A. Shimoni, A. Nagler, 2018, The EBMT Handbook.

High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma

A. Nagler, R. Yerushalmi, A. Shimoni, 2021, Bone Marrow Transplantation.

Treosulfan-based or busulfan-based conditioning for allogeneic transplantation: the role of dose intensity.

A. Shimoni, 2019, The Lancet. Haematology.

Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation

A. Nagler, R. Yerushalmi, A. Shimoni, 2021, International Journal of Hematology.

The Role of Donor Selection for a Second Allogeneic Stem Cell Transplantation in Patients with AML Relapsing after a First Transplant; A Study on Behalf of the Acute Leukemia Working Party of EBMT

N. Kröger, M. Labopin, P. Chevallier, 2018, Biology of Blood and Marrow Transplantation.

Adding methylprednisone to cyclosporine and methotrexate safely reduces acute graft vs host disease in people receiving sibling-donor bone marrow transplants

A. Nagler, A. Shimoni, 2001 .

The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT

M. Perales, M. V. D. van den Brink, A. Nagler, 2021, Blood advances.

Comparison between Anti-Thymocyte Globulin and Alemtuzumab and the Possible Impact of KIR-Ligand Mismatch in Melphalan/Fludarabine Dose-Reduced Conditioning Followed by HLA-Matched and Mismatched Unrelated Stem Cell Transplantation in Patients with Multiple Myeloma.

S. Iacobelli, A. Nagler, K. Peggs, 2004 .

Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel

A. Nagler, R. Yerushalmi, M. Besser, 2022, Leukemia & lymphoma.

Combination of Rituximab with Initial Chemotherapy Improves Outcome of Primary Mediastinal B-Cell Lymphoma: A Retrospective Analysis of a Single Institution Cohort

A. Nagler, A. Shimoni, I. Hardan, 2007 .

Blocking of Transient Receptor Potential Vanilloid1 (TRPV1) Promotes Lysosomal Destabilization and Enhances Bortezomib-induced ER Stress and Cell Death via HSP70 and LAMP3 Down-regulation: Novel Therapeutic Target for Multiple Myeloma

A. Nagler, A. Peled, A. Shimoni, 2017, Clinical Lymphoma Myeloma and Leukemia.

Celiac Disease Resolution After Allogeneic Bone Marrow Transplantation is Associated with Absence of Gliadin-Specific Memory Response by Donor-Derived Intestinal T-cells

S. Polak‐Charcon, I. Barshack, Y. Maor, 2013, Journal of Clinical Immunology.

Discovery of tumoricidal DNA oligonucleotides by response-directed in vitro evolution

I. Bachelet, Erez Lavi, I. Avivi, 2020, Communications Biology.

Discovery of tumoricidal DNA aptamers by effect-directed in-vitro evolution

I. Bachelet, Erez Lavi, I. Avivi, 2019, bioRxiv.

The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway

A. Nagler, E. Galun, A. Peled, 2016, Clinical Cancer Research.

BKT140 Is a Novel CXCR4 Antagonist with Stem Cell Mobilization and Antimyeloma Effects: An Open-Label First Human Trial In Patients with Multiple Myeloma Undergoing Stem Cell Mobilization for Autologous Transplantation

A. Nagler, E. Galun, A. Peled, 2010 .

Safety and Efficacy of CD19-CAR T Cells in Richter's Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia

A. Nagler, R. Yerushalmi, D. Lavie, 2020 .

Increasing the dose intensity of the conditioning regimen prior to allogeneic hematopoietic stem cell transplant: the role of pharmacokinetic monitoring

A. Nagler, A. Shimoni, 2010, Leukemia & lymphoma.

Repeated Courses of Orally Administered Fecal Microbiota Transplantation for the Treatment of Steroid Resistant and Steroid Dependent Intestinal Acute Graft Vs. Host Disease: A Pilot Study (NCT 03214289)

Itai Sharon, O. Koren, A. Nagler, 2018, Blood.

Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis

N. Schmitz, I. Yakoub-Agha, P. Dreger, 2023, Leukemia.

Baseline Renal Function and Albumin are Powerful Predictors for Allogeneic Transplantation-Related Mortality.

A. Nagler, J. Cornelissen, A. Shimoni, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Discovery of tumoricidal DNA oligonucleotides by response-directed in vitro evolution

I. Bachelet, Erez Lavi, I. Avivi, 2020, Communications Biology.

Cryofibrinogenemia and skin necrosis in a patient with diffuse large cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation

A. Shimoni, M. Körbling, J. Molldrem, 2000, Bone Marrow Transplantation.

Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience.

A. Nagler, A. Shimoni, 2004, Current hematology reports.

Prolymphocytic transformation of B‐chronic lymphocytic leukemia presenting as malignant ascites and pleural effusion

A. Berrebi, A. Shimoni, L. Shvidel, 1998, American journal of hematology.

Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience

A. Nagler, A. Gafter-Gvili, A. Shimoni, 2010, Infection.

Harnessing graft‐versus‐malignancy: non‐myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy

N. Ueno, S. Kornblau, R. Champlin, 2000 .

Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience.

N. Kröger, I. Yakoub-Agha, A. Nagler, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age>55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning

N. Kröger, A. Zander, A. Nagler, 2005, Leukemia.

Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma

A. Nagler, R. Yerushalmi, A. Shimoni, 2023, Leukemia & lymphoma.

Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.

A. Nagler, A. Polliack, A. Shimoni, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Application of machine learning algorithms for clinical predictive modeling: a data-mining approach in SCT

R. Unger, A. Nagler, A. Shimoni, 2014, Bone Marrow Transplantation.

Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias

N. Kröger, A. Zander, A. Nagler, 2003, Leukemia.

Double umbilical cord blood transplant: more than a cell dose?

A. Nagler, R. Yerushalmi, A. Shimoni, 2010, Leukemia & lymphoma.

Interest of Non-Myeloablative Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma: A Multicenter Retrospective Study.

I. Yakoub-Agha, A. Nagler, M. Mohty, 2008 .

Anti-T Lymphocyte Globulin (ATG) Induces Generation of Regulatory T Cells, at Least Part of Them Express Activated CD44

A. Nagler, R. Yerushalmi, A. Shimoni, 2011, Journal of Clinical Immunology.

Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

A. Nagler, M. Leiba, R. Yerushalmi, 2016 .

Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced

A. Nagler, A. Chetrit, R. Yerushalmi, 2013, Leukemia.

Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome

N. Kröger, M. Labopin, I. Yakoub-Agha, 2014, Bone Marrow Transplantation.

Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients

L. Miller, M. Misgav, A. Shimoni, 2022, Transfusion Medicine and Hemotherapy.

Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation

A. Nagler, N. Amariglio, A. Shimoni, 2008, Leukemia.

The expanding horizon of immunotherapy in the treatment of malignant disorders: Allogeneic hematopoietic stem cell transplantation and beyond

A. Nagler, A. Shimoni, P. Tsirigotis, 2014, Annals of medicine.

Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fluda

A. Nagler, R. Yerushalmi, A. Shimoni, 2007, Leukemia.

Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma

A. Nagler, S. Zwas, R. Yerushalmi, 2008, Bone Marrow Transplantation.

Intravenous Busulfan-Based Conditioning Prior to Allogeneic Stem Cell Transplantation in Adults Patients with AML - An ALWP-EBMT Survey.

A. Zander, M. Labopin, A. Nagler, 2007 .

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

A. Nagler, R. Yerushalmi, A. Shimoni, 2006, Leukemia.

Assessment of the coagulation profile in hemato-oncological patients receiving ATG-based conditioning treatment for allogeneic stem cell transplantation

A. Nagler, B. Sela, A. Shimoni, 2004, Bone Marrow Transplantation.

Fecal microbiota transplantation in capsules for the treatment of steroid refractory and steroid dependent acute graft vs. host disease: a pilot study.

O. Koren, R. Yerushalmi, A. Eshel, 2024, Bone marrow transplantation.

Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC

A. Nagler, J. Rowe, A. Shimoni, 2012, Hematological oncology.

Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.

N. Kröger, D. Atanackovic, A. Zander, 2009, Experimental hematology.

Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced‐intensity allografting

N. Kröger, A. Nagler, E. Holler, 2012, British journal of haematology.

G-CSF-primed BM for allogeneic SCT: revisited

A. Nagler, A. Shimoni, I. Pessach, 2015, Bone Marrow Transplantation.

Autologous T cells control B-chronic lymphocytic leukemia tumor progression in human-->mouse radiation chimera.

A. Berrebi, A. Canaan, A. Shimoni, 1999, Cancer research.

Human/mouse radiation chimera generated from PBMC of B chronic lymphocytic leukemia patients with autoimmune hemolytic anemia produce anti-human red cell antibodies

A. Canaan, A. Shimoni, Y. Reisner, 1997, Leukemia.

Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet™) combined morphological and cytogenetical analysis

A. Nagler, L. Trakhtenbrot, N. Amariglio, 2002, Leukemia.

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up

A. Nagler, R. Yerushalmi, A. Shimoni, 2010, Leukemia.

Nilotinib Treatment Post - Allogeneic Stem Cell Transplantation (alloSCT) in Advanced (>CP1) Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL).

A. Nagler, N. Amariglio, R. Somech, 2009 .

Generation of non-alloreactive anti-viral central memory CD8 human veto T cells for cell therapy.

K. Rezvani, M. Eyrich, A. Shimoni, 2023, Transplantation and cellular therapy.

CT in the clinical and prognostic evaluation of acute graft-vs-host disease of the gastrointestinal tract.

R. Yerushalmi, A. Shimoni, L. Guranda, 2012, The British journal of radiology.

Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity

A. Nagler, R. Yerushalmi, A. Shimoni, 2012, Bone Marrow Transplantation.

Non-myeloablative stem cell transplantation (NST): chimerism testing as guidance for immune-therapeutic manipulations

A. Nagler, A. Shimoni, A. Shimoni, 2001, Leukemia.

Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike

A. Nagler, A. Shimoni, A. Shimoni, 2012, Bone Marrow Transplantation.

J. Esteve, M. Labopin, A. Nagler, 2015, The oncologist.

Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation.

A. Neumann, A. Nagler, T. Efferth, 2011, Antiviral research.